As the firm seeks to expand use of its MammaPrint and TheraPrint tests and move other breast cancer tests into the clinical realm, it decided that the public markets would be the only possible route to raise the necessary funds.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.